Drugs / fotemustine
fotemustine
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 26 trials | ||||||
| Phase 2 | NCT05274139 | Mar 2017 → Mar 2019 | primary central nervous system lymphoma | Mingzhi Zhang | Completed | No outcome recorded |
| Phase 2 | NCT01983124 | Feb 2013 → Apr 2014 | metastatic melanoma | Paola Queirolo | Completed | No outcome recorded |
| Phase 2 | NCT01474239 | Nov 2011 → Dec 2013 | glioblastoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01654692 | Jun 2010 → May 2012 | metastatic melanoma | Italian Network for Tumor Biotherapy | Completed | No outcome recorded |
| Phase 2 | NCT01069627 | Dec 2006 → Jul 2009 | melanoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00560118 | Aug 2003 → Aug 2008 | cutaneous melanoma | Institut du Cancer de Montpellier - Val d'Aurelle | Terminated | No outcome recorded |
| Phase 32 trials · 2 missed | ||||||
| Phase 3 | NCT00110123 | Jan 2005 → Jun 2011 | metastatic melanoma, uveal melanoma | European Organisation for Research and Treatment of Cancer - EORTC | Terminated | Missed primary Stop: Enrollment |
| Phase 3 | NCT01359956 | Apr 2002 → Feb 2011 | melanoma | National Cancer Institute, Naples | Completed | Missed primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT01960192 | Jun 2012 → Jun 2016 | primary central nervous system lymphoma | Mingzhi Zhang | Unknown | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1/2 | NCT04831658 Background | Mar 2021 → Sep 2023 | primary central nervous system lymphoma | Mingzhi Zhang | Unknown | No outcome recorded |
| Phase 3 | NCT05647954 Background | Dec 2022 → Dec 2024 | neuroendocrine neoplasm | Taizhou Hanzhong Biomedical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT02460068 Comparator | Dec 2012 → Jan 2018 | metastatic malignant neoplasm in the brain | Italian Network for Tumor Biotherapy Foundation | Unknown | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fotemustine | “This study was an open-label, single-arm, phase 1/2 trial evaluating orelabrutinib combined with an anti-programmed cell death protein-1 (PD-1) antibody and a non-methotrexate...” PMID 41485126 ↗ Jan 202611“cisplatin 75 mg/sqm, day1, every 6 weeks; fotemustine 100 mg/sqm, day2, every 6 weeks; lipiodol is usually 5-10 ml” NCT05647954 ↗ “FVD regimen(fotemustine, teniposide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt” NCT01960192 ↗ “FTD regimen(fotemustine, temozolomide and dexamethasone),fotemustine 100mg/m2” NCT05274139 ↗ |
| Known as | Fotemustina | ChEMBL registry synonym — accepted as the source's own label CHEMBL549386 ↗ |
| Known as | Fotemustine (Muphoran) | “Fotemustine (Muphoran);” NCT02460068 ↗1“Fotemustine (Muphoran)” NCT01654692 ↗ |
| Known as | Muphoran | ChEMBL registry synonym — accepted as the source's own label CHEMBL549386 ↗ |
| Known as | Mustophorane | ChEMBL registry synonym — accepted as the source's own label CHEMBL549386 ↗ |
| Known as | S-10036 | ChEMBL registry synonym — accepted as the source's own label CHEMBL549386 ↗ |
| Action | Inhibit | “In vitro, fotemustine inhibited VEGF-C release by melanoma cells without inducing significant cell death.” PMID 21030496 ↗ Oct 2010 |
| Modality | Small molecule | — CHEMBL549386 ↗ |
| Route | Intravenous | “Patients receive fotemustine IV over 1 hour on days 1, 8, and 15 (induction course).” NCT00110123 ↗ |